Company Overview of Wanbang Biopharmaceuticals Co., Ltd.
Wanbang Biopharmaceuticals Co., Ltd. focuses on developing, manufacturing, and selling pharmaceuticals for patients of diabetes and related cardiovascular diseases. Its products include animal insulin, Glimepiride tablets, Meglumine Adenosine Cyclophosphate, EPO, Bangtan(Telmisatan), and Heparin sodium. The company’s products also comprise aloe compound capsules for clearing liver-heat, relaxing bowels, and calming heart for tranquillization; and products in the fields of chemicals, pharmaceuticals, and biotech, such as Human Interferon ?, Human Erythropoietin, Streptokinase, and Pemetrexed disodium. It sells products through a network of distributors and sales representatives in China and i...
No.6 Yangshan Road
Jinshanqiao Economic Zone
Founded in 1981
Key Executives for Wanbang Biopharmaceuticals Co., Ltd.
Vice President and Secretary
Compensation as of Fiscal Year 2016.
Wanbang Biopharmaceuticals Co., Ltd. Key Developments
Rockwell Medical, Inc. Enters into Licensing and Manufacturing Supply Agreements with Wanbang Biopharmaceutical Co., Ltd
Feb 16 16
On February 16, 2016, Rockwell Medical, Inc. announced that it entered into exclusive licensing and manufacturing supply agreements with Wanbang Biopharmaceutical Co. Ltd. for the rights to commercialize the company's Triferic and Calcitriol for end stage-renal disease patients, that also includes new therapeutic indications for Triferic, in the People's Republic of China. Triferic is the company's proprietary iron replacement and hemoglobin maintenance drug for treating anemia. Calcitriol is the company's generic (active vitamin D) injection for treatment of secondary hyperparathyroidism in dialysis patients. Under the terms of the agreement, the company will become the exclusive distributor for Triferic and Calcitriol in China for an initial commercial term of ten years, with an extended term of 10 or more years based on achievement of annual minimum purchase requirements. In consideration for the exclusive rights, the company will receive from the company an upfront fee plus regulatory and revenue milestone payments totaling $39 million in aggregate. Notably, the company will receive ongoing earnings from product sales of Triferic and Calcitriol, and other additional Triferic therapeutic indications. The company retains manufacturing responsibility of all products. The company is required to achieve annual minimum purchase requirements to retain exclusive commercialization rights. In addition to the hemodialysis indication, the company has the exclusive right to develop and commercialize Triferic for new therapeutic indications for the Chinese market. The company is responsible for all clinical, regulatory and marketing expenses for Triferic and Calcitriol in China as well as development and regulatory costs for new Triferic indications.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 22, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries